Confronto
Dulaglutide vs. Survodutide
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Metabolico
Metabolico
N. CAS
923950-08-7
2179963-22-7
Peso molecolare
59670 g/mol
4727 g/mol
Emivita
110 h
168 h
Sequenza
GLP-1(7-37)-Variante kovalent verbunden mit modifiziertem humanen IgG4-Fcmodifiziertes 29-Aminosäuren-Peptid mit FettsäureseitenketteMeccanismo d'azione
Dulaglutide
Dulaglutide consists of two modified GLP-1(7-37) sequences covalently linked to a human IgG4-Fc. The Fc fusion increases molecular weight substantially (~60 kDa), reduces renal filtration and extends the half-life to several days. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon, delays gastric emptying and modulates central satiety signalling.
Survodutide
Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
5
4
di cui sull'uomo
5
4
Effetti registrati
3
3
Contraddizioni aperte
1
1
Eventi avversi documentati
2
2
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Dulaglutide and Survodutide?
- Dulaglutide is classified as "Metabolico", while Survodutide is classified as "Metabolico". Dulaglutide: GLP-1 receptor agonist designed as a fusion protein of two modified GLP-1(7-37) sequences covalently linked to a human IgG4-Fc fragment. FDA-approved 2014 (Trulicity) for type 2 diabetes; EMA approval 2014. Survodutide: Synthetic peptide that simultaneously activates the GLP-1 and glucagon receptors. Developed by Boehringer Ingelheim and Zealand Pharma; in phase-3 trials for obesity (SYNCHRONIZE) and MASH. No marketing approval yet. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Dulaglutide or Survodutide?
- The highest available evidence level is "RCT sull'uomo" for Dulaglutide and "RCT sull'uomo" for Survodutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Dulaglutide and Survodutide in Germany and the United States?
- Germania: Dulaglutide — Su prescrizione, Survodutide — Non approvato. Stati Uniti: Dulaglutide — Su prescrizione, Survodutide — Non approvato. These are factual summaries with source and review date on the individual pages.